Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and … Read more
Akebia Ther (AKBA) - Net Assets
Latest net assets as of December 2025: $32.61 Million USD
Based on the latest financial reports, Akebia Ther (AKBA) has net assets worth $32.61 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($376.56 Million) and total liabilities ($343.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $32.61 Million |
| % of Total Assets | 8.66% |
| Annual Growth Rate | N/A |
| 5-Year Change | -55.94% |
| 10-Year Change | -52.13% |
| Growth Volatility | 270.97 |
Akebia Ther - Net Assets Trend (2012–2025)
This chart illustrates how Akebia Ther's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Akebia Ther (2012–2025)
The table below shows the annual net assets of Akebia Ther from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $32.61 Million | +166.30% |
| 2024-12-31 | $-49.19 Million | -60.82% |
| 2023-12-31 | $-30.58 Million | -684.78% |
| 2022-12-31 | $5.23 Million | -92.93% |
| 2021-12-31 | $74.01 Million | -70.11% |
| 2020-12-31 | $247.62 Million | -37.27% |
| 2019-12-31 | $394.76 Million | -37.92% |
| 2018-12-31 | $635.93 Million | +432.91% |
| 2017-12-31 | $119.33 Million | +75.18% |
| 2016-12-31 | $68.12 Million | -48.00% |
| 2015-12-31 | $131.00 Million | +25.87% |
| 2014-12-31 | $104.08 Million | +238.41% |
| 2013-12-31 | $30.76 Million | +1247.81% |
| 2012-12-31 | $-2.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Akebia Ther's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 162411686600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.01% |
| Other Comprehensive Income | $6.00K | 0.02% |
| Other Components | $1.72 Billion | 5263.13% |
| Total Equity | $32.61 Million | 100.00% |
Akebia Ther Competitors by Market Cap
The table below lists competitors of Akebia Ther ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sella Capital Real Estate Ltd
PINK:STCPF
|
$340.23 Million |
|
Chatham Lodging Trust REIT
NYSE:CLDT
|
$340.42 Million |
|
Hellenic Exchanges - Athens Stock Exchange SA
PINK:HEHSF
|
$340.54 Million |
|
Xiamen Solex High-Tech Industries Co Ltd
SHG:603992
|
$340.62 Million |
|
Arafura Resources Limited
DU:REB
|
$340.10 Million |
|
Zhejiang Kan Specialities Material Co Ltd
SHE:002012
|
$340.02 Million |
|
Iteos Therapeutics Inc
NASDAQ:ITOS
|
$339.96 Million |
|
Hynar Water Group Co. Ltd.
SHE:300961
|
$339.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Akebia Ther's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -49,185,000 to 32,610,000, a change of 81,795,000.
- Net loss of 5,345,000 reduced equity.
- New share issuances of 66,679,000 increased equity.
- Other factors increased equity by 20,461,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.34 Million | -16.39% |
| Share Issuances | $66.68 Million | +204.47% |
| Other Changes | $20.46 Million | +62.74% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Akebia Ther's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.75x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.26 | $1.49 | x |
| 2013-12-31 | $2.07 | $1.49 | x |
| 2014-12-31 | $6.76 | $1.49 | x |
| 2015-12-31 | $4.95 | $1.49 | x |
| 2016-12-31 | $1.81 | $1.49 | x |
| 2017-12-31 | $2.74 | $1.49 | x |
| 2018-12-31 | $5.44 | $1.49 | x |
| 2019-12-31 | $3.33 | $1.49 | x |
| 2020-12-31 | $1.79 | $1.49 | x |
| 2021-12-31 | $0.45 | $1.49 | x |
| 2022-12-31 | $0.03 | $1.49 | x |
| 2023-12-31 | $-0.16 | $1.49 | x |
| 2024-12-31 | $-0.23 | $1.49 | x |
| 2025-12-31 | $0.13 | $1.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Akebia Ther utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.26%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 11.55x
- Recent ROE (-16.39%) is above the historical average (-198.32%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.93 Million |
| 2013 | -42.81% | 0.00% | 0.00x | 1.13x | $-16.24 Million |
| 2014 | -35.58% | -5288.81% | 0.01x | 1.07x | $-47.44 Million |
| 2015 | -46.35% | 0.00% | 0.00x | 1.09x | $-73.82 Million |
| 2016 | -199.28% | -8843.45% | 0.01x | 4.41x | $-142.56 Million |
| 2017 | -64.45% | -43.21% | 0.49x | 3.05x | $-88.85 Million |
| 2018 | -27.03% | -82.75% | 0.21x | 1.57x | $-235.50 Million |
| 2019 | -70.84% | -83.48% | 0.43x | 1.95x | $-319.13 Million |
| 2020 | -141.29% | -118.48% | 0.46x | 2.60x | $-374.63 Million |
| 2021 | -330.87% | -114.65% | 0.40x | 7.15x | $-252.27 Million |
| 2022 | -1801.64% | -32.22% | 0.82x | 68.08x | $-94.75 Million |
| 2023 | 0.00% | -26.68% | 0.81x | 0.00x | $-48.87 Million |
| 2024 | 0.00% | -43.33% | 0.73x | 0.00x | $-64.49 Million |
| 2025 | -16.39% | -2.26% | 0.63x | 11.55x | $-8.61 Million |
Industry Comparison
This section compares Akebia Ther's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Akebia Ther (AKBA) | $32.61 Million | 0.00% | 10.55x | $340.21 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |